# P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

> **NCT03288493** · PHASE1,PHASE2 · TERMINATED · sponsor: **Poseida Therapeutics, Inc.** · enrollment: 105 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** P-BCMA-101 CAR-T cells
- **DRUG:** Rimiducid

## Key facts

- **NCT ID:** NCT03288493
- **Lead sponsor:** Poseida Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-20
- **Primary completion:** 2022-04-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 105 (ACTUAL)
- **Why stopped:** Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.
- **Last updated:** 2024-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288493, "P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03288493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*